Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Bokemeyer

Showing results (191-200 of 663) with videos related to

Pageof 67
Sort By:
Onkologie|December 18, 2009
Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 yearsIna Thöm, Claudia Rogers, Birte Andritzky, et al.
Anti-Cancer Drugs|February 1, 2007
An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumorsKarin Oechsle, Friedemann Honecker, Christian Kollmannsberger, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 18, 2003
Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumorsFriedemann Honecker, Frank Mayer, Hans Stoop, et al.
Investigational New Drugs|October 31, 2003
An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcomaPeter Reichardt, Karin Oechsle, Daniel Pink, et al.
Cancer Letters|May 23, 2012
Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repairAnnabelle E Fenske, Stephanie Glaesener, Carsten Bokemeyer, et al.
Oncology|March 11, 2010
Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumorKarin Oechsle, Anja Lorch, Friedemann Honecker, et al.
International Journal of Clinical and Experimental Pathology|August 12, 2015
Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localizationNathaniel Melling, Ronald Simon, Jakob R Izbicki, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 28, 2025
Real-World Data on Outcome of Burkitt Lymphoma and Burkitt Leukemia Treated According to the GMALL B-ALL/NHL 2002 Protocol: A Tertiary Center ExperienceRicardo Kosch, Christoph Schaefers, Christian Frenzel, et al.
European Urology|June 3, 2011
EAU guidelines on testicular cancer: 2011 updatePeter Albers, Walter Albrecht, Ferran Algaba, et al.
The Oncologist|October 27, 2005
Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia SurveyPeter Barrett-Lee, Carsten Bokemeyer, Pere Gascón, et al.
Pageof 67

Showing results (191-200 of 663) with videos related to

Sort By:
Pageof 67
Onkologie|December 18, 2009
Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 yearsIna Thöm, Claudia Rogers, Birte Andritzky, et al.
Anti-Cancer Drugs|February 1, 2007
An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumorsKarin Oechsle, Friedemann Honecker, Christian Kollmannsberger, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 18, 2003
Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumorsFriedemann Honecker, Frank Mayer, Hans Stoop, et al.
Investigational New Drugs|October 31, 2003
An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcomaPeter Reichardt, Karin Oechsle, Daniel Pink, et al.
Cancer Letters|May 23, 2012
Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repairAnnabelle E Fenske, Stephanie Glaesener, Carsten Bokemeyer, et al.
Oncology|March 11, 2010
Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumorKarin Oechsle, Anja Lorch, Friedemann Honecker, et al.
International Journal of Clinical and Experimental Pathology|August 12, 2015
Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localizationNathaniel Melling, Ronald Simon, Jakob R Izbicki, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 28, 2025
Real-World Data on Outcome of Burkitt Lymphoma and Burkitt Leukemia Treated According to the GMALL B-ALL/NHL 2002 Protocol: A Tertiary Center ExperienceRicardo Kosch, Christoph Schaefers, Christian Frenzel, et al.
European Urology|June 3, 2011
EAU guidelines on testicular cancer: 2011 updatePeter Albers, Walter Albrecht, Ferran Algaba, et al.
The Oncologist|October 27, 2005
Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia SurveyPeter Barrett-Lee, Carsten Bokemeyer, Pere Gascón, et al.
Pageof 67